http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102195657-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-351 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D309-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-55 |
filingDate | 2013-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2020-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2020-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-102195657-B1 |
titleOfInvention | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
abstract | A novel double-targeted bifunctional anti-influenza drug formed by conjugation with an anti-inflammatory agent is disclosed. Exemplary drugs according to the present invention are caffeic acid (CA)-bearing zanamivir (ZA) conjugates ZA-7-CA (1), ZA for simultaneous inhibition of influenza virus neuraminidase and inhibition of inflammatory cytokines. -7-CA-amide (7) and ZA-7-Nap (43). Synthetic methods for the preparation of such enhanced anti-influenza conjugate drugs are provided. Synthetic bifunctional ZA conjugates act synergistically on the protection of mice lethal infection with H1N1 or H5N1 influenza virus. The efficacy of the ZA-7-CA, ZA-7-CA-amide and ZA-7-Nap conjugates is much greater than that of the anti-inflammatory and ZA combination therapy. |
priorityDate | 2012-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1166.